The downgrade from Neutral to Underperform by a major analyst firm like B of A Securities, along with a drastic reduction in the price target from $10 to $2, suggests a significant negative sentiment towards Fulcrum Therapeutics. This is likely to lead to a decrease in investor confidence and a short-term decline in the stock price.